Siesta Medical

What Siesta Medical does

Siesta Medical, Inc. is a privately held medical device company founded in 2009 and headquartered in Los Gatos, California, that develops the AIRLIFT procedure system for the surgical treatment of obstructive sleep apnea (OSA). Its core technology comprises the Encore System — an integrated suite of knotless suture anchors and instruments used to perform hyoid suspension and tongue suspension — together with the Revolution Suture Passer, a specialized instrument for passing suspension lines around the hyoid bone. The product family is protected by nine issued U.S. patents and is cleared by the FDA under multiple 510(k) authorizations (initial clearance in September 2011, expanded clearance in May 2019), has a CE Mark from June 2012, and is supported by clinical evidence including a 74–75% mean reduction in AHI and 91% avoidance of tracheostomy in referred patients.

The company sells its devices directly to ENT specialists (otolaryngologists), oral surgeons, and other surgical specialists through a field sales force that also provides procedure training and support, supplemented by a patient-facing doctor directory (airliftsleep.com) that drives demand to enrolled physicians. Revenue is generated primarily through one-time hardware sales of integrated device kits (Encore System catalog FG0002, Revolution Suture Passer FG0008, Encore Revision Kit FG0005), with procedure economics supported by reimbursement from CMS and major private payers for hyoid suspension and from CMS and some private payers for tongue suspension. The company operates with a small team of approximately 1–10 employees and has not disclosed institutional ownership, recent funding rounds, or revenue figures.

Siesta Medical's strategic positioning is anchored in offering a minimally invasive, adjustable, and reversible alternative to complex OSA surgeries and hypoglossal nerve stimulation implants, at substantially lower cost and with established insurance coverage. Its go-to-market emphasizes physician education through surgical conferences (Combined Otolaryngology Spring Meetings, ISSS, AAO-HNSF), peer-reviewed publications, and clinical society recognition — most notably the ISSS 2024 Position Statement classifying hyoid suspension as effective and non-investigational — as the primary levers for expanding its addressable surgeon base across the U.S.

Name

Siesta Medical

Legal name

Siesta Medical, Inc.

Website

https://siestamedical.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

1–10 employees

Short description

Siesta Medical is a privately held medical device company that develops the AIRLIFT procedure system — including the Encore System and Revolution Suture Passer — for minimally invasive surgical treatment of obstructive sleep apnea, selling directly to ENT specialists and oral surgeons in the United States.

Ownership category

akta.pro rank

Product category

Sleep Apnea Treatment Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Sleep Surgery & Snoring (ENT) (HLAKAMAH)

akta.pro secondary industry

Airway Management Devices (ET Tubes, LMAs, Tracheostomy, Suction) (HLAHAGAF)

Keywords

• Sleep apnea treatment
• Hyoid suspension devices
• Tongue suspension implants
• ENT surgical devices
• Minimally invasive OSA

Headquarters

HQ city

Los Gatos

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Medical Device Hardware Sales: Siesta Medical sells the Encore System and Revolution Suture Passer as integrated medical device kits. The Encore System (catalog FG0002) and Revolution Suture Passer (catalog FG0008) are sold to physicians who perform the AIRLIFT procedure. Additional products include the Encore Revision Kit (catalog FG0005). Federal (USA) law restricts these devices to sale by or on the order of a physician.
2. Insurance Reimbursement: The AIRLIFT procedure is reimbursed by CMS (Centers for Medicare & Medicaid Services) and all major private payers for hyoid suspension. Tongue suspension is reimbursed by CMS and some private payers.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Siesta Medical develops and sells the AIRLIFT procedure system for treating obstructive sleep apnea (OSA), comprising the Encore System (integrated suture anchors and surgical instruments for hyoid and tongue suspension) and the Revolution Suture Passer. The products are FDA 510(k)-cleared medical devices sold to ENT specialists and oral surgeons for performing minimally invasive outpatient airway-stabilization procedures.

Product overview

Siesta Medical offers the AIRLIFT™ system for obstructive sleep apnea treatment, which consists of the Encore™ System (suture anchors and instruments for hyoid and tongue suspension) and the Revolution™ Suture Passer. These integrated products work together to perform the AIRLIFT procedure for hyoid suspension and/or tongue suspension, providing a minimally invasive surgical alternative to CPAP. The Encore Revision Kit supports post-operative adjustments. All components are designed for outpatient procedures with broad insurance coverage.

Differentiator

Problem solved

Functional benefit

Brands

• AIRLIFT: The AIRLIFT procedure - a quick, safe and lasting treatment to unblock the airway for obstructive sleep apnea. Uses hyoid and tongue suspension techniques.
• Encore System
• Revolution Suture Passer

Quantifiable outcome

• 74% reduction in Sleep Apnea (AHI) with AIRLIFT hyoid suspension
• +4 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Koninklijke Philips: Philips Respironics is a major CPAP and sleep therapy device manufacturer. Like ResMed, it anchors the non-surgical OSA standard of care and represents the incumbent option that surgical alternatives like AIRLIFT must displace when patients fail or refuse CPAP.
• Stryker: Stryker is a major surgical instruments and orthopedic implants company. It acquired Ross Creek Medical, where Siesta's CTO previously served as CEO, and represents both a strategic acquirer profile and a broader competitive reference point in surgical device commercialization.
• ResMed: ResMed is the global leader in CPAP therapy and broader sleep-disordered breathing treatment. While it does not directly compete in surgical OSA, its CPAP franchise defines the front-line treatment that AIRLIFT and other surgical alternatives position themselves against for non-adherent patients.
• LivaNova: LivaNova has historically been involved in implantable neurostimulation including for sleep apnea (it sold its sleep apnea franchise to Inspire). It remains a broader neuromodulation incumbent relevant to the surgical OSA competitive landscape.
• Medtronic: Medtronic is a diversified medical device leader with ENT and surgical instrument franchises. It has historically acquired OSA-adjacent assets (e.g., Coalescent Surgical, where Siesta's CEO previously worked) and represents a potential strategic acquirer or competitive threat in surgical OSA.

Direct peers

• Inspire Medical Systems: Inspire is the dominant OSA surgical implant company, commercializing hypoglossal nerve stimulation for moderate-to-severe OSA. It directly competes with AIRLIFT for the same ENT surgeon customer and the same CPAP-intolerant patient population, but with a more invasive, higher-cost implantable approach.

Emerging players

• Nyxoah: Nyxoah is developing a next-generation, leadless hypoglossal nerve stimulation system for OSA. It targets the same surgical OSA market as Inspire and AIRLIFT, focusing on a less invasive implant approach and competing for ENT adoption.
• ProSomnus Sleep Technologies: ProSomnus produces precision oral appliance therapy devices for OSA. It offers a non-surgical CPAP alternative that competes for similar patient populations to AIRLIFT, particularly those with mild-to-moderate OSA.
• SomnoMed: SomnoMed manufactures oral appliances (mandibular advancement devices) for mild-to-moderate OSA and snoring. It competes for CPAP-intolerant patients with a non-surgical alternative, sitting adjacent to Siesta's surgical positioning in the OSA treatment pathway.

Regional players

• Integra LifeSciences: Integra LifeSciences develops surgical instruments and implants across ENT, neurosurgery, and other specialties. It serves the same ENT surgical customer base as Siesta and provides a broader specialty surgical instruments peer comparable in product category and call point.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UC8MlGp7ZN70PWCbi_XPoUZA
• Facebookfacebook.com/Siestamedicalsleep/?fref=nf
• LinkedInlinkedin.com/company/siesta-medical-inc.

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Siesta Medical